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Abstract
Background Metabolic syndrome is a cluster of factors that increase the risk of cardiovascular disease and include: dia-
betes and prediabetes, abdominal obesity, elevated triglycerides, low high-density lipoprotein cholesterol and high blood-
pressure. However, the role of the pharmacist in the metabolic syndrome has not yet been fully explored. Aim of the review 
This systematic review aimed to critically appraise, synthesise, and present the available evidence on pharmacists’ input to 
the screening, prevention and management of metabolic syndrome. Method The final protocol was based on the “Preferred 
Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P)”. Studies published in English from 
January 2008 to March 2020 reporting any pharmacist activities in the screening, prevention or management of metabolic 
syndrome were included. Databases searched were Medline, Cumulative Index to Nursing and Allied Health Literature, 
International Pharmaceutical Abstracts, Cochrane and Google Scholar. Studies were assessed for quality by two researchers, 
data extracted and findings synthesised using a narrative approach. Results Of the 39,430 titles reviewed, ten studies were 
included (four were randomised controlled trials). Most studies focused on pharmacist input to metabolic syndrome screening 
and management. Screening largely involved communicating metabolic parameters to physicians. Management of metabolic 
syndrome described pharmacists collaborating with members of the multidisciplinary team. A positive impact was reported 
in all studies, including achieving metabolic syndrome parameter goals, reverting to a non-metabolic syndrome status and, 
improved medication adherence. The populations studied were paediatrics with risk factors, adults with comorbidities and 
psychiatric patients. Integration of the pharmacist within the multidisciplinary team, an easy referral process and accessibility 
of service were potential facilitators. Inadequate funding was the key barrier. Conclusion The studies describing pharmacist 
input in metabolic syndrome provide limited evidence of positive outcomes from screening and management as part of col-
laborative practice. Further work is required to provide more robust evidence of effectiveness and cost-effectiveness while 
considering key barriers.
Keywords Management · Metabolic syndrome · Pharmacist role · Prevention · Screening · Systematic review
Impacts on Practice
• There is a lack of evidence on the role for the pharmacist 
in metabolic syndrome (MetS), the viable models of care 
and the beneficial population.
• The review suggests that pharmacists can effectively 
screen patients for MetS, and participate in the preven-
tion and management amongst most at-risk populations 
and within different settings to enhance patient care.
• Further research is warranted to determine the readiness 
and acceptance for the pharmacist to intervene in MetS 
from the pharmacists, physicians and patient’s perspec-
tive.
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supplementary material, which is available to authorized users.
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Introduction
The International Diabetes Federation (IDF) estimates 
that metabolic syndrome (MetS) affects one-quarter of 
the world’s population, doubling the risk of coronary 
heart disease, increasing the risk of mortality secondary 
to coronary heart disease by three-fold and increasing the 
risk of developing Type 2 diabetes mellitus (DM) fivefold 
[1]. MetS is a global concern due to its increasing preva-
lence, primarily due to obesity [1]. As a result, a num-
ber of international organisations including the IDF, the 
American Heart Association, the National Heart, Lung and 
Blood Institutes (NHLBI), the World Heart Federation, 
the International Atherosclerosis Society and the Inter-
national Association for the Study of Obesity harmonised 
the criteria for metabolic syndrome (MetS). The health 
consequences associated with MetS are significant, [2, 3] 
as are the direct and indirect burdens on the healthcare 
system and society more generally [4–8].
It is estimated that more than 80% of cardiovascular 
disease (CVD) complications secondary to MetS can be 
prevented by optimizing blood pressure and lipid profiles 
[9], with the most effective, evidence-based measures 
being lifestyle interventions usually increased physical 
activity and adopting a healthier diet [10–13]. Pharmaco-
logical treatment is considered in cases of failure of non-
pharmacological interventions in achieving modifiable risk 
factor reduction [14, 15].
To date, most evidence on health professional input to 
MetS management has centred on physicians and nurses 
[16]. While these roles are well-defined, there is less evi-
dence supporting pharmacist involvement in MetS man-
agement. There is potential for pharmacists to apply their 
expert medication knowledge and clinical skills to enhance 
the care of patients who are at risk of or have established 
MetS.
The clinical and patient-facing roles of the pharmacist 
in the management of acute and chronic conditions have 
developed significantly since the seminal publication by 
Hepler and Strand [17]. This introduced the concept of 
pharmaceutical care, which was a paradigm shift from 
dispensing functions towards more proactive, collabora-
tive roles in eliminating preventable drug-related prob-
lems (DRPs) [17]. Several systematic reviews and meta-
analyses have provided substantial evidence of the impact 
of pharmacist’s intervention relating to specific MetS risk 
factors. Four systematic reviews and a meta-analysis of 
randomised controlled trials (RCTs) reported the effec-
tiveness of the pharmacists’ interventions in the manage-
ment of Type 1 and 2 DM, reducing HbA1c levels and 
improving medication and lifestyle adherence following 
pharmacist intervention [18]. Further systematic reviews 
and meta-analyses have provided evidence of reduction 
in systolic and diastolic blood pressure in hypertension 
(HTN) [19, 20], weight loss in obesity [21, 22] and reduc-
tion in CVD related hospitalization and mortality [23].
Furthermore, there is evidence of positive impact in other 
chronic conditions, including asthma and chronic obstructive 
pulmonary disease (COPD) [24, 25].
Growing evidence has suggested that collaborative multi-
disciplinary care approach in many disciplines is best prac-
tice [26]. This supports achieving the aim of better popula-
tion health, better patient experience and low per capita cost 
[27].
A preliminary search of the Cochrane Library of System-
atic Reviews and Meta-analysis and the International Data-
base of the Prospectively Registered Systematic Review in 
Health and Social Science (PROSPERO) using the terms, 
‘pharmacist’ and ‘metabolic syndrome’, yielded no related 
published or ongoing systematic reviews. A search in Med-
line using the same terms identified a body of primary lit-
erature sufficient for a systematic review to be undertaken.
Aim of the review
The aim of this systematic review was to critically appraise, 
synthesise, and present the evidence on pharmacists’ input to 
the screening, prevention and management of MetS. Specific 
objectives were to determine the types of pharmacist input 
reported in the studies; determine the impact of the reported 
input; characterise the populations who could benefit most 
from the input; and identify the facilitators and barriers to 
the effective implementation of pharmacist input.
Ethics approval
The Institutional Review Board (IRB) of the Medical 
Research Committee at Hamad Medical Corporation (HMC) 
in Qatar has confirmed that no ethics approval is required 
since this is a review.
Method
Protocol development
The systematic review protocol was developed based on the 
Preferred Reporting Items for Systematic Review and Meta-
Analysis Protocols (PRISMA-P) 2015 guidance [28] (Online 
Appendix A) and registered in the International Prospective 
Register of Systematic Reviews (PROSPERO) [29].
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Inclusion and exclusion criteria
The standard systematic review PICO (population, interven-
tion, comparator and outcomes) approach was employed 
[30].
Type of participants
All studies irrespective of population groups were included 
in the review.
Type of interventions
All pharmacist activities in the screening, prevention or 
management of MetS were included.
Type of comparator
All studies were included whether or not there was a control 
group comparing the impact with or without a pharmacist’s 
input.
Type of outcome
All studies were assessing the pharmacists’ input in the 
screening, management and prevention of MetS.
The outcomes were diverse and included the follow-
ing: comparisons of different models of pharmacist input 
in MetS, descriptions of the process of development of the 
models, and the clinical outcomes of such interventions.
Types of studies to be included
All studies were included irrespective of design. The initial 
search indicated that the first relevant article was published 
in 2008; hence, all studies published between 2008 and 
March 2020, in the English language were included.
Exclusion Criteria
Grey literature was excluded due to the potentially limited 
quality and difficulties in searching and retrieval [31].
Search strategy and data sources
The electronic search strategy was guided by the “Peer 
Review of Electronic Search Strategies” (PRESS) checklist 
[32]. An initial search of Medline and Cumulative Index to 
Nursing and Allied Health Literature (CINAHL) was con-
ducted, using keywords of ‘pharma*’ AND ‘metabolic syn-
drome’ to identify further keywords and search terms. The 
search string then applied to Medline, CINAHL, Cochrane, 
International Pharmaceutical Abstracts (IPA) and Google 
Scholar was (‘Metabolic syndrome*’ OR ‘syndrome x’ OR 
‘Insulin resistance  syndrome*’ OR ‘Dysmetabolic  syn-
drome*’ OR “Hypertriglyceridemic waist*’ OR ‘Obe-
sity syndrome*’ OR ‘Metabolic Cardiovascular Syndrome’ 
OR ‘Reaven Syndrome X’ OR ‘Atherothrombogenic syn-
drome’) AND ‘Pharm*’.
The reference lists of all identified articles were hand 
searched to identify any further relevant articles. Attempts 
were made to contact corresponding authors where data 
were missing or incomplete.
Quality assessment and data extraction
Eligible studies were assessed for quality using standardised 
quality assessment tools, the Cochrane bias assessment tool 
and the National Heart, Lung and Blood Institute (NHLBI) 
quality assessment tools [33, 34]. Quality assessment using 
these tools was undertaken independently by two reviewers, 
with any disagreements resolved by discussion and refer-
ral to a third reviewer if necessary. RCTs were deemed of 
good quality if all criteria were of low bias risk as judged 
by the assessor, fair if the study had one high bias risk or 
two uncertain bias criteria, and poor if two or more high or 
uncertain bias criteria [33].
A data extraction tool was developed by adapting and cus-
tomizing the “Data collection form for intervention review—
RCTs and non-RCTs” from the Cochrane Collaboration [35]. 
Information was extracted by two independent reviewers.
Data synthesis
Given the lack of homogeneity of study aims, participants 
and outcome measures, a narrative approach to data synthe-
sis was undertaken, using text and tables aligned to each of 
the review objectives.
Results
The results of the search process
The initial search yielded 39,430 studies. Screening of the 
titles excluded 39,363 titles, and abstract screening excluded 
a further 53. Of the 14 remaining studies, four were excluded 
on full-text review. Of the ten studies included in the follow-
ing stages four were RCTs; four were cross-sectional design, 
one a before-and-after study and one was quality improve-
ment project (Fig. 1).
 International Journal of Clinical Pharmacy
1 3
Quality assessment
Quality assessment of all included studies is reported in 
Tables 1 and 2. The RCTs had low bias for the primary out-
come measures (Table 1). The key limitation of the cross-
sectional studies was the absence of a rationale for, or cal-
culation of, sample size (Table 2). The overall potential risk 
of bias of the before-and-after study was assessed to be low. 
Restricting the assessment to a single time point (measur-
ing the outcome once after the outreach visits) and single 
hospital ward (the study was held in a psychiatric ward of 
the hospital) were key study limitations (Table 2).
Data extraction
Most of the studies (n = 7) were conducted in South and 
North America, with two in Europe and one in the Middle 
IPA 
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Fig. 1  Flow diagram of the literature review process
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East. A total of 1728 participants were included, with sam-
ple size ranging from 17 to 650. The four RCTs evaluated 
the impact of pharmacist contribution in MetS manage-
ment versus conventional care. One before-and-after study 
assessed the impact of a pharmacist outreach visit to imple-
ment a MetS screening program in a hospital ward. The 
four cross-sectional studies mainly assessed the usefulness 
or the implementation of pharmacist-led Mets screening. 
The quality improvement project evaluated the patient load 
before and after expansion, with special focus on the type 
of pharmacist input. Table 3 describes the study findings in 
relation to the review objectives.
Data synthesis
Review objective 1: Description of pharmacist input
Study settings were community pharmacies [36, 37] ambula-
tory outpatient clinics (family medicine, community health 
centres and psychiatric clinics) [38–42], and pharmacist out-
reach visits to psychiatric patients in a hospital ward setting 
[43] and as part of a home healthcare service [44].
The pharmacist input was described in all the studies 
with varying levels of detail provided. Pharmacist screen-
ing of participants for MetS against validated criteria was 
described in eight studies [37–43] with screening results 
communicated to the relevant physician [41, 42]. In two 
studies, screening of other CV risk factors, using the 
Framingham risk assessment tool, was additionally reported 
[36, 37]. Various approaches to participant recruitment 
were described: clinic referral-based recruitment in three 
studies [41, 42, 45], appointment booking following appro-
priate advertisement in the media and the surrounding clin-
ics [36], recruiting walk-ins to the community pharmacy 
[37] or through pharmacist patient history review [38]. Two 
studies did not clearly report the recruitment process [39, 
40].
All RCTs described the baseline assessment of all 
patients with regular follow-up of the intervention arm, with 
both baseline and follow up conducted by the pharmacist 
[38–40, 44]. The pharmacist attended the clinic appointment 
along with the physician in one study [38] and documented 
and communicated a plan to the physician in three studies 
[39, 40, 44]. In two studies, pharmacists also provided rec-
ommendations relating to laboratory testing and the need 
to prescribe new medications for undiagnosed conditions 
[38–40, 44, 45]. Lifestyle modification recommendations 
were provided by the pharmacist in five studies [38, 39, 
41, 42, 44, 45], with only one of these measuring related 
outcomes using a nonvalidated questionnaire at three to six 
months [36] (Table 3).
Review objective 2: Impact of pharmacist role in MetS
Eight studies aimed to determine the impact of the phar-
macist input. In the studies focusing on screening, the per-
centage of the newly diagnosed participants with MetS was 
reported, these participants would not have been diagnosed 
if the pharmacy screening service not been available [37, 41, 
42]. These patients were followed-up by referral [41], or by 
communicating the relevant clinical parameters to the physi-
cian [36, 42]. One study demonstrated an improvement in 
the quality and quantity of documentation completed by phy-
sicians relating to MetS screening [43]. No further patient 
follows up was reported in one study [37].
The impact in MetS management in collaboration with the 
multidisciplinary team (MDT) was measured in four RCTs 
and one cross-sectional study, with improvement of anthropo-
metric and metabolic parameters being the primary outcome 
measures [38–40, 44]. Additionally, determination of patient 
Table 1  Quality assessment of randomised controlled trials studies [33]
L low risk, H high risk, NA not applicable, U unclear
Hammad et al. 
2011 [38]
Plaster et al. 2012 
[39]
Schneiderhan et al. 
2014 [40]
Azevedo 
et al. 2017 
[44]
Random sequence generation (selection bias) L L L L
Allocation concealment (selection bias) L L L L
Blinding of participants and personnel (performance bias) NA NA NA NA
Blinding of outcome assessment (detection bias) L L L L
Incomplete outcome data (attrition bias) L L L L
Selective outcome reporting? (reporting bias) L L L L
Other bias L L L L
The quality rating Good Good Good Good
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medication adherence was conducted in one study [44]. All 
but one study reported positive impact in terms of; achiev-
ing MetS parameter goals, reverting to non-MetS status, 
improved medication adherence and self-reported improved 
lifestyle modification. The study conducted in a psychiatric 
outpatient clinic failed to show significant improvement in 
metabolic parameters after the 12 months study period [40].
Review objective 3: The beneficiary population
Adults with comorbidities of MetS elements such as DM, 
HTN, dyslipidemia and obesity, were included in five studies 
[37–39, 44, 45]. Psychiatric patients receiving antipsychotic 
medications were targeted in three studies [40, 41, 45], since 
these medications are associated with significant weight gain 
Table 2  Quality assessment of cross-sectional studies [34], and before-and-after (pre-post) studies with no control group [34] respectively
Y Yes, N No, NA not applicable, CD cannot determine
Schneiderhan 
et al. 2009 
[41]
Olenak and 
Calpin 2010 
[36]
Benavides 
et al. 2011 
[42]
Via-Sosa 
et al. 2014 
[37]
Kjeldsen 
et al. 2013 
[43]
Cross-sectional studies
1. Was the research question or objective in this paper clearly 
stated?
Y Y Y Y
2. Was the study population clearly specified and defined? N Y Y Y
3. Was the participation rate of eligible persons at least 50%? CD CD Y CD
4. Were all the subjects selected or recruited from the same or 
similar populations (including the same time period)? Were inclu-
sion and exclusion criteria for being in the study prespecified and 
applied uniformly to all participants?
Y Y Y Y
5. Was a sample size justification, power description, or variance 
and effect estimates provided?
N N N Y
6. Were the outcome measures (dependent variables) clearly 
defined, valid, reliable, and implemented consistently across all 
study participants?
Y Y Y Y
Before-and-after (pre-post) studies
1. Was the study question or objective clearly stated? Y
2. Were eligibility/selection criteria for the study population pre-
specified and clearly described?
Y
3. Were the participants in the study representative of those who 
would be eligible for the test/service/intervention in the general or 
clinical population of interest?
Y
4. Were all eligible participants that met the prespecified entry 
criteria enrolled?
CD
5. Was the sample size sufficiently large to provide confidence in the 
findings?
CD
6. Was the test/service/intervention clearly described and delivered 
consistently across the study population?
Y
7. Were the outcome measures prespecified, clearly defined, valid, 
reliable, and assessed consistently across all study participants?
Y
8. Were the people assessing the outcomes blinded to the partici-
pants’ exposures/interventions?
N
9. Was the loss to follow-up after baseline 20% or less? Were those 
lost to follow-up accounted for in the analysis?
NA
10. Did the statistical methods examine changes in outcome meas-
ures from before to after the intervention? Were statistical tests 
done that provided P values for the pre-to-post changes?
Y
11. Were outcome measures of interest taken multiple times before 
the intervention and multiple times after the intervention (i.e., did 
they use an interrupted time-series design)?
N
12. If the intervention was conducted at a group level (e.g., a whole 
hospital, a community, etc.) did the statistical analysis take into 
account the use of individual-level data to determine effects at the 
group level?
N
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ec
tiv
en
es
s 
of
 an
 ed
uc
ati
on
 
pr
ov
id
ed
 by
 
th
e p
ha
rm
ac
ist
 
to
 en
co
ur
ag
e 
pa
tie
nt
s t
o m
ak
e 
lif
es
ty
le 
ch
an
ge
s”
Pr
os
pe
cti
ve
 cr
os
s-
se
cti
on
al 
stu
dy
Ba
se
lin
e s
cr
ee
ni
ng
 
in
di
ca
ted
 th
at
86
 (3
6%
) h
ad
 
M
etS
. U
sin
g 
Fr
am
in
gh
am
 ri
sk
 
as
se
ss
m
en
t, 
20
 
(8
.3%
) w
ar
e a
t 
hi
gh
 ri
sk
 of
 C
HD
 
(≥
 20
 10
-y
ea
r r
isk
 
of
 C
HD
)
87
% 
wi
th
 M
etS
 
se
lf-
re
po
rte
d 
lif
es
ty
le 
ch
an
ge
s 
fo
llo
wi
ng
 ed
uc
a-
tio
n p
ro
vi
de
d b
y 
th
e p
ha
rm
ac
ist
No
 fu
rth
er
 de
tai
ls 
we
re
 pr
ov
id
ed
23
9 v
ol
un
tee
rs 
ov
er
 18
 ye
ar
s o
f 
wi
th
 no
 hi
sto
ry
 
of
 co
ro
na
ry
 he
ar
t 
di
se
as
e (
CH
D)
Ba
se
lin
e s
cr
ee
n-
in
g f
or
 M
etS
 an
d 
Fr
am
in
gh
am
 
10
-y
ea
r r
isk
 
as
se
ss
m
en
t
Pr
ov
isi
on
 of
 ed
u-
ca
tio
na
l l
ife
sty
le 
in
ter
ve
nt
io
n a
t 
ba
se
lin
e f
or
 al
l 
pa
tie
nt
s
Pr
ov
isi
on
 of
 
sc
re
en
in
g r
es
ul
ts 
to
 th
e p
hy
sic
ian
As
se
ss
in
g u
pt
ak
e 
of
 li
fes
ty
le 
m
od
ifi
ca
tio
ns
 
su
gg
es
ted
 by
 a 
no
n-
va
lid
ate
d 
qu
es
tio
nn
air
e
Ea
rli
er
 de
tec
tio
n 
of
 M
ets
 th
ro
ug
h 
th
e p
ha
rm
ac
ist
-
led
 sc
re
en
in
g 
pr
og
ra
m
Ea
rli
er
 in
ter
ve
n-
tio
n b
y p
ro
vi
di
ng
 
ed
uc
ati
on
 to
 th
e 
pa
tie
nt
s a
nd
 re
l-
ev
an
t h
ea
lth
ca
re
 
re
fer
ra
l (
58
% 
di
sc
us
se
d t
he
ir 
re
su
lts
 w
ith
 a 
ph
ys
ici
an
)
Th
e p
re
va
len
ce
 
of
 M
etS
 w
as
 
hi
gh
er
 in
 ol
de
r 
ad
ul
ts 
ag
ed
 
49
.9 
± 
17
 ye
ar
s 
an
d t
ho
se
 w
ith
 
DM
 or
 pr
e-
DM
Fa
ci
lit
at
or
s
Co
m
m
un
ity
 ph
ar-
m
ac
y s
ett
in
g p
lac
-
in
g t
he
 ph
ar
m
ac
ist
 
in
 an
 ex
ce
lle
nt
 
po
sit
io
n t
o p
ro
vi
de
 
a s
cr
ee
ni
ng
 se
rv
ice
Eff
ec
tiv
e c
om
-
m
un
ica
tio
n w
ith
 
ph
ys
ici
an
s
Pa
tie
nt
 en
ga
ge
m
en
t 
an
d o
wn
er
sh
ip
 of
 
th
eir
 he
alt
h
Av
ail
ab
ili
ty
 of
 P
OC
 
de
vi
ce
s
Eff
ec
tiv
e a
dv
er
tis
-
in
g o
f s
cr
ee
ni
ng
 
se
rv
ice
Ba
rr
ie
rs
Fi
na
nc
ial
 co
sts
 of
 
co
ns
um
ab
les
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pu
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n w
ho
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d b
en
efi
t m
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fro
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pu
t
Fa
cil
ita
to
rs 
an
d b
ar-
rie
rs 
to
 th
e e
ffe
cti
ve
 
im
pl
em
en
tat
io
n o
f 
M
etS
Be
na
vi
de
s e
t a
l.,
 
20
11
, C
am
er
on
 
[4
2]
“T
o e
va
lu
ate
 th
e 
ro
le 
of
 a 
cli
ni
ca
l 
ph
ar
m
ac
ist
 (C
P)
 
in
 sc
re
en
in
g 
ch
ild
re
n a
nd
 
ad
ol
es
ce
nt
s f
or
 
co
m
po
ne
nt
s o
f 
th
e M
etS
”
Pr
os
pe
cti
ve
, c
ro
ss
-
se
cti
on
al 
stu
dy
Of
 th
e 2
5 p
ar-
tic
ip
an
ts 
wh
o 
co
m
pl
ete
d t
he
 
stu
dy
 1 
(4
%)
 
ha
d 3
 pa
ra
m
-
ete
rs 
of
 M
etS
, 7
 
(2
8%
) h
ad
 tw
o 
co
m
po
ne
nt
s, 
an
d 
9 (
36
%)
 ha
d o
nl
y 
on
e
Tr
ea
tm
en
t r
ec
om
-
m
en
da
tio
ns
 
we
re
 m
ad
e 
fo
r 1
7 (
68
%)
 
pa
rti
cip
an
ts 
an
d 
co
m
m
un
ica
ted
 to
 
th
e p
ae
di
atr
ici
an
. 
Al
l w
er
e n
on
-
ph
ar
m
ac
ol
og
ica
l 
in
ter
ve
nt
io
ns
Hi
gh
-ri
sk
 ch
ild
re
n 
ag
ed
 10
-1
8 y
ea
rs 
ol
d, 
of
 M
ex
ica
n–
Am
er
ica
n o
rig
in
 
in
 a 
ru
ra
l a
m
bu
la-
to
ry
 he
alt
h c
en
tre
As
se
ss
in
g t
he
 
pa
rti
cip
an
ts 
fo
r 
ea
ch
 co
m
po
ne
nt
 
of
 M
etS
Ed
uc
ati
ng
 th
e 
pa
rti
cip
an
ts 
ab
ou
t 
ex
er
cis
e
Pr
ov
id
in
g t
he
 pa
e-
di
atr
ici
an
 w
ith
 
sc
re
en
in
g r
es
ul
ts 
an
d m
an
ag
em
en
t 
re
co
m
m
en
da
tio
ns
Ea
rly
 de
tec
tio
n 
of
 M
etS
 an
d t
he
 
co
m
po
ne
nt
s i
n a
 
pa
ed
iat
ric
 po
pu
-
lat
io
n (
68
% 
wi
th
 
at 
lea
st 
1 M
etS
 
pa
ra
m
ete
r)
En
ha
nc
e t
he
 ea
rly
 
m
an
ag
em
en
t o
f 
M
etS
 th
ro
ug
h 
th
e p
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vi
sio
n o
f 
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tio
n t
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ici
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s k
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t t
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gr
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sio
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se
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d D
M
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fer
ra
ls 
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cia
n a
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 di
eti
tia
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fo
r f
ur
th
er
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se
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en
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ed
iat
ric
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tie
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th
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po
ne
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 fa
cto
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M
etS
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fir
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de
gr
ee
 
fam
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 hi
sto
ry
 of
 
DM
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 ac
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th
os
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ni
gr
ica
ns
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or
s
Pr
ev
io
us
 ex
pe
rie
nc
e 
in
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ar
m
ac
ist
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ni
ng
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 a 
sc
re
en
in
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cli
ni
c
Eff
ec
tiv
e c
ol
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or
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tio
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ith
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si-
cia
ns
Ba
rr
ie
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Fi
na
nc
ial
 co
sts
 of
 
sta
ff 
an
d c
on
su
m
a-
bl
es
Ru
ra
l a
re
as
 an
d l
ac
k 
of
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ce
ss
 to
 he
alt
h-
ca
re
 pr
ov
isi
on
La
ck
 of
 co
ns
en
su
s 
on
 M
etS
 de
fin
iti
on
 
in
 ch
ild
re
n a
nd
 
ad
ol
es
ce
nt
s
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m
 in
pu
t
Fa
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d b
ar-
rie
rs 
to
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e e
ffe
cti
ve
 
im
pl
em
en
tat
io
n o
f 
M
etS
Ha
m
m
ad
 et
 al
., 
20
11
, J
or
da
n [
38
]
“T
o d
es
cr
ib
e t
he
 
cli
ni
ca
l b
en
efi
ts 
of
 a 
ph
ys
ici
an
-
cli
ni
ca
l p
ha
rm
a-
cis
t c
ol
lab
or
ati
on
 
in
 ac
hi
ev
in
g 
be
tte
r g
lyc
em
ic 
co
nt
ro
l a
nd
 be
tte
r 
lip
id
 an
d B
P 
m
ea
su
re
m
en
ts 
in
 pa
tie
nt
s w
ith
 
m
eta
bo
lic
 sy
n-
dr
om
e a
s d
efi
ne
d 
by
 N
CE
P/
AT
P 
III
 
gu
id
eli
ne
s”
RC
T 
no
n-
bl
in
de
d
Of
 th
e 1
99
 pa
r-
tic
ip
an
ts,
 w
he
n 
co
m
pa
rin
g t
he
 
co
nt
ro
l g
ro
up
 
to
 th
e i
nt
er
ve
n-
tio
n g
ro
up
, 2
2 
(2
4.7
%)
 ve
rsu
s 4
3 
(3
9.1
%)
, r
es
pe
c-
tiv
ely
 (P
 =
 0.
03
2)
 
we
re
 sh
ift
ed
 
fro
m
 th
e M
etS
 to
 
no
ne
-M
etS
 st
atu
s. 
Th
er
e w
as
 a 
sig
-
ni
fic
an
t r
ed
uc
tio
n 
in
 T
G,
 an
d B
P 
in
 th
e i
nt
er-
ve
nt
io
n g
ro
up
 
co
m
pa
re
d t
o t
he
 
co
nt
ro
l g
ro
up
. 
30
8 p
ha
rm
ac
ist
 
in
ter
ve
nt
io
ns
 
we
re
 pr
ov
id
ed
 
to
 pa
tie
nt
s a
nd
 
ph
ys
ici
an
s
Hi
gh
-ri
sk
 pa
tie
nt
s 
id
en
tifi
ed
 at
 
fam
ily
 m
ed
ici
ne
 
ou
tp
ati
en
t c
lin
ics
Re
cr
ui
t t
he
 id
en
ti-
fie
d p
ati
en
ts 
wi
th
 
su
sp
ec
ted
 M
etS
In
ter
vi
ew
 pa
tie
nt
 
pr
io
r t
o t
he
 
ap
po
in
tm
en
t w
ith
 
th
e p
hy
sic
ian
De
ve
lo
p i
nd
iv
id
u-
ali
se
d c
ar
e p
lan
s 
in
 co
lla
bo
ra
tio
n 
wi
th
 ph
ys
ici
an
s
Pr
ov
id
e m
ed
ica
-
tio
n a
nd
 li
fes
ty
le 
m
od
ifi
ca
tio
n 
ed
uc
ati
on
 w
ith
 
ha
nd
ou
ts
Pr
ov
id
e r
ec
om
m
en
-
da
tio
ns
 to
 st
ar
t 
ne
w 
tre
atm
en
t 
an
d l
ab
or
ato
ry
 
m
on
ito
rin
g
Pr
ov
id
e p
ati
en
t 
fo
llo
w-
up
Im
pr
ov
e M
etS
 st
a-
tu
s a
m
on
gs
t t
he
 
pa
rti
cip
an
ts 
in
 
th
e i
nt
er
ve
nt
io
n 
gr
ou
p b
y 3
9.1
%
Im
pr
ov
e t
he
 el
e-
m
en
ts 
of
 M
etS
 in
 
th
e i
nt
er
ve
nt
io
n 
gr
ou
p i
nc
lu
d-
in
g T
G 
re
du
ce
d 
by
 15
 m
g/
dL
 
m
or
e t
ha
n i
n t
he
 
co
nt
ro
l g
ro
up
 
(P
 =
 0.
02
9)
Im
pr
ov
e B
P 
re
du
c-
tio
n w
as
 si
gn
ifi
-
ca
nt
ly
 hi
gh
er
 in
 
th
e i
nt
er
ve
nt
io
n 
gr
ou
p (
SB
P 
12
.2 
± 
20
 m
m
Hg
 
an
d D
BP
 
7.2
 ±
 12
.6 
m
m
Hg
 
(P
 =
 0.
04
9)
In
cr
ea
se
 th
e 
pa
tie
nt’
s k
no
wl
-
ed
ge
 an
d a
wa
re
-
ne
ss
 of
 M
etS
Pa
tie
nt
s w
ith
 
hy
pe
rte
ns
io
n a
nd
 
hi
gh
 tr
ig
lyc
er
id
es
Fa
ci
lit
at
or
s
Eff
ec
tiv
e c
ol
lab
or
a-
tio
n w
ith
 th
e p
hy
si-
cia
ns
 in
 as
se
ss
in
g 
an
d m
an
ag
in
g 
M
etS
Lo
gi
sti
ca
l i
ss
ue
s 
as
so
cia
ted
 w
ith
 
cli
ni
c s
ite
En
ga
gi
ng
 th
e p
ati
en
t 
an
d e
nc
ou
ra
gi
ng
 
ow
ne
rsh
ip
 an
d 
ad
he
re
nc
e
Eff
ec
tiv
e p
ati
en
t 
fo
llo
w-
up
Ba
rr
ie
rs
La
ck
 of
 av
ail
ab
il-
ity
 of
 re
so
ur
ce
s 
in
clu
di
ng
 ph
ar
m
a-
cis
t t
im
e
La
ck
 of
 th
e f
or
m
al 
in
teg
ra
tio
n o
f t
he
 
M
etS
 sc
re
en
in
g 
an
d m
an
ag
em
en
t 
pr
ot
oc
ol
s w
ith
in
 
th
e h
ea
lth
 sy
ste
m
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an
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ar-
rie
rs 
to
 th
e e
ffe
cti
ve
 
im
pl
em
en
tat
io
n o
f 
M
etS
Pl
as
ter
 et
 al
., 2
01
2, 
Br
az
il 
[3
9]
“T
o d
ete
rm
in
e 
th
e i
m
pa
ct 
of
 a 
ph
ar
m
ac
eu
tic
al 
ca
re
 pr
og
ra
m
 in
 a 
sa
m
pl
e o
f p
ub
lic
 
ou
tp
ati
en
ts 
wi
th
 
M
etS
”
RC
T 
no
n-
bl
in
de
d
96
 (8
0%
) o
ut
 of
 
12
0 p
ar
tic
ip
an
ts 
ha
d M
etS
.
At
 ba
se
lin
e, 
dr
ug
-
re
lat
ed
 pr
ob
lem
s 
(D
RP
s) 
we
re
 
id
en
tifi
ed
 re
lat
in
g 
to
 effi
cie
nc
y, 
sa
fet
y a
nd
 ne
ce
s-
sit
y.
At
 fo
llo
w 
up
, a
ll 
we
re
 im
pr
ov
ed
.
Im
pr
ov
em
en
t i
n 
th
e i
nt
er
ve
nt
io
n 
gr
ou
p w
as
 fo
un
d 
in
 al
l t
he
 m
ea
s-
ur
ed
 pa
ra
m
ete
rs 
af
ter
 6 
m
on
th
s 
fro
m
 ba
se
lin
e. 
Th
is 
wa
s s
tat
ist
i-
ca
lly
 si
gn
ifi
ca
nt
 
fo
r a
lm
os
t a
ll 
pa
ra
m
ete
rs
Di
ab
eti
c p
ati
en
ts 
wi
th
 M
etS
 id
en
ti-
fie
d a
t o
ut
pa
tie
nt
 
co
m
m
un
ity
 
he
alt
h c
en
tre
s
Ba
se
lin
e a
ss
es
s-
m
en
t t
o o
bt
ain
 
th
e d
em
og
ra
ph
i-
ca
l d
ata
 an
d 
id
en
tif
y a
ny
 D
RP
Pr
ov
id
e p
ha
rm
a-
ce
ut
ica
l i
nt
er
ve
n-
tio
ns
 ta
rg
eti
ng
 
th
e p
ro
pe
r 
m
ed
ica
tio
ns
 us
e 
an
d l
ife
sty
le 
m
od
ifi
ca
tio
ns
In
fo
rm
 th
e 
ph
ys
ici
an
s o
f 
th
e p
ha
rm
ac
ist
 
in
ter
ve
nt
io
ns
A 
sig
ni
fic
an
t 
re
du
cti
on
 in
 
co
ro
na
ry
 he
ar
t 
di
se
as
e (
22
 ±
 2 
to
 14
 ±
 2%
; 
P <
 0.
01
).
83
% 
re
so
lu
tio
n a
nd
 
10
0%
 im
pr
ov
e-
m
en
t o
f t
he
 D
RP
s 
an
d o
pt
im
iza
tio
n 
of
 dr
ug
 tr
ea
tm
en
t
In
cr
ea
se
 th
e m
ed
i-
ca
tio
ns
 ad
he
r-
en
ce
 in
di
ca
ted
 
in
di
re
ctl
y b
y t
he
 
im
pr
ov
em
en
t 
of
 th
e c
lin
ica
l 
ou
tco
m
es
Im
pr
ov
e B
P 
-1
3 ±
 3 
m
m
Hg
 
(P
 <
 0.
05
)
In
cr
ea
se
 w
eig
ht
 
re
du
cti
on
 
-2
.6 
± 
1 k
g i
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e i
nt
er
ve
nt
io
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gr
ou
p
Di
ab
eti
c, 
hy
pe
r-
ten
siv
e o
be
se
 
pa
tie
nt
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ci
lit
at
or
s
Eff
ec
tiv
e c
ol
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or
a-
tio
n w
ith
 th
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hy
si-
cia
ns
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in
g a
 pa
rt 
of
 th
e 
m
ul
tid
isc
ip
lin
ar
y 
tea
m
 (M
DT
) a
nd
 
ha
vi
ng
 a 
de
fin
ed
 
ro
le
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eq
ua
te 
fin
an
cia
l 
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so
ur
ce
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pl
yi
ng
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e-
de
fin
ed
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ar
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a-
ce
ut
ica
l f
ra
m
ew
or
k 
(D
ád
er
 m
eth
od
)
Ba
rr
ie
rs
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m
iti
ng
 th
e c
om
-
m
un
ity
 he
alt
h 
ce
nt
re
 ph
ar
m
ac
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ro
le 
to
 di
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sin
g
La
ck
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so
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ng
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d b
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n o
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M
etS
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se
n e
t a
l.,
 
20
13
, D
en
m
ar
k 
[4
3]
“T
o e
va
lu
ate
 th
e 
eff
ec
t o
f o
ut
re
ac
h 
vi
sit
 by
 cl
in
i-
ca
l p
ha
rm
ac
ist
s 
to
 su
pp
or
t t
he
 
im
pl
em
en
tat
io
n 
of
 sc
re
en
in
g o
f 
M
etS
 at
 a 
ps
yc
hi
-
atr
ic 
wa
rd
”
Be
fo
re
-a
nd
-a
fte
r 
stu
dy
Im
pr
ov
em
en
t i
n 
ut
ili
sa
tio
n o
f 
M
etS
 sc
re
en
in
g 
sh
ee
ts 
by
 45
% 
(fr
om
 34
 (3
6%
) 
to
 91
 (8
1%
), 
P <
 0.
00
1)
, B
ett
er
 
do
cu
m
en
tat
io
n o
f 
sc
re
en
in
g v
alu
es
 
24
 (2
6%
) t
o 9
1 
(8
1%
) (
P <
 0.
00
1)
 
an
d b
ett
er
 
id
en
tifi
ca
tio
n o
f 
M
etS
 (9
.3 
(1
0%
) 
ve
rsu
s 5
0 (
45
%)
, 
P <
 0.
00
1)
20
5 P
ati
en
ts 
ov
er
 
18
 ye
ar
s w
ith
 
sc
hi
zo
ph
re
ni
a 
or
 aff
ec
tiv
e 
di
so
rd
er
s, 
in
 
a p
sy
ch
iat
ric
 
wa
rd
 fo
r a
t l
ea
st 
10
 da
ys
 an
d o
n 
an
tip
sy
ch
ot
ics
 or
 
m
oo
d-
sta
bi
liz
in
g 
m
ed
ici
ne
s w
er
e 
in
clu
de
d i
n t
he
 
stu
dy
 (9
3 b
efo
re
 
th
e o
ut
re
ac
h v
isi
t 
an
d 1
12
 af
ter
)
Au
di
tin
g p
hy
si-
cia
n a
dh
er
en
ce
 
to
 ap
pr
op
ria
te 
do
cu
m
en
tat
io
n
Ho
ld
in
g a
 w
ee
kl
y 
co
nf
er
en
ce
 w
ith
 
th
e p
hy
sic
ian
s 
an
d n
ur
se
s t
o 
di
sc
us
s t
he
 au
di
t 
re
su
lts
Pr
ov
id
in
g p
ati
en
t-
sp
ec
ifi
c r
ec
om
-
m
en
da
tio
ns
Su
cc
es
sfu
l 
im
pl
em
en
tat
io
n 
of
 a 
ps
yc
hi
atr
ic 
ho
sp
ita
l-b
as
ed
 
sc
re
en
in
g p
ro
-
gr
am
 in
di
ca
ted
 as
 
fo
llo
ws
:
In
cr
ea
se
 ut
ili
za
tio
n 
of
 th
e s
cr
ee
ni
ng
 
sh
ee
ts 
by
 45
%
Im
pr
ov
e t
he
 qu
ali
ty
 
of
 th
e s
cr
ee
ni
ng
 
by
 55
%
Ea
rli
er
 de
tec
tio
n 
of
 an
tip
sy
ch
ot
ic-
in
du
ce
d M
etS
 by
 
35
%
Ea
rli
er
 m
an
ag
e-
m
en
t o
f t
he
 
id
en
tifi
ed
 M
etS
 
ca
se
s a
m
on
gs
t 
ho
sp
ita
liz
ed
 ps
y-
ch
iat
ric
 pa
tie
nt
s
Ad
ul
t h
os
pi
tal
ise
d 
pa
tie
nt
s r
ec
eiv
in
g 
an
tip
sy
ch
ot
ics
 or
 
m
oo
d-
sta
bi
liz
er
s
Fa
ci
lit
at
or
s
Av
ail
ab
ili
ty
 of
 
ap
pr
op
ria
te 
do
cu
-
m
en
tat
io
n w
ith
 
au
di
t f
or
 co
m
pl
i-
an
ce
Eff
ec
tiv
e c
ol
lab
or
a-
tio
n w
ith
 th
e M
DT
, 
wi
th
 a 
de
fin
ed
 ro
le
Ba
rr
ie
rs
Di
ffi
cu
lt 
be
ha
vi
ou
rs 
of
 th
e p
sy
ch
iat
ric
 
pa
tie
nt
s
La
ck
 of
 pr
op
er
 co
m
-
m
un
ica
tio
n a
nd
/
or
 do
cu
m
en
tat
io
n 
wi
th
 th
e g
en
er
al 
pr
ac
tit
io
ne
rs 
in
 th
e 
co
m
m
un
ity
 he
alt
h 
ce
nt
re
s
Un
av
ail
ab
ili
ty
 of
 
th
e I
T 
so
ftw
ar
e t
o 
fac
ili
tat
e d
oc
um
en
-
tat
io
n a
nd
 co
m
-
m
un
ica
tio
n
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lat
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M
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ob
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tiv
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De
sc
rip
tio
n o
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ph
ar
m
ac
ist
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pu
t
Im
pa
ct 
of
 th
e i
de
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tifi
ed
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pu
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Po
pu
lat
io
n w
ho
 
wo
ul
d b
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efi
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os
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fro
m
 in
pu
t
Fa
cil
ita
to
rs 
an
d b
ar-
rie
rs 
to
 th
e e
ffe
cti
ve
 
im
pl
em
en
tat
io
n o
f 
M
etS
Vi
a-
So
sa
 et
 al
., 
20
14
, S
pa
in
 [3
7]
“T
he
 m
ain
 ai
m
 of
 
th
e s
tu
dy
 w
as
 to
 
de
ter
m
in
e t
he
 
pr
ev
ale
nc
e o
f 
pr
e-
M
etS
, t
he
 
se
co
nd
ar
y a
im
s 
we
re
 to
 st
ud
y 
th
e p
re
se
nc
e o
f 
ot
he
r c
ar
di
ov
as
-
cu
lar
 ri
sk
 fa
cto
rs 
an
d d
ete
rm
in
e 
pa
tie
nt
s’ 
ca
rd
io
-
va
sc
ul
ar
 ri
sk
”
Cr
os
s-s
ec
tio
na
l, 
de
sc
rip
tiv
e s
tu
dy
Am
on
g t
he
 
65
0 s
cr
ee
ne
d 
pa
rti
cip
an
ts,
 
12
4 (
21
.9%
) h
ad
 
pr
e-
M
etS
. O
f t
he
 
stu
dy
 po
pu
lat
io
n;
 
31
9 (
49
.1%
) w
er
e 
hy
pe
rte
ns
ive
, 
26
2 (
40
.3%
) h
ad
 
ab
do
m
in
al 
ob
e-
sit
y, 
17
9 (
27
.5%
) 
ha
d h
ig
h F
BG
, 
13
1 (
20
.1%
) h
ad
 
hi
gh
 T
G 
an
d 1
09
 
(1
6.8
%)
 ha
d l
ow
 
HD
L-
C.
 27
% 
ha
d 
no
t b
ee
n p
re
vi
-
ou
sly
 di
ag
no
se
d 
wi
th
 dy
sli
pi
de
m
ia 
or
 hy
pe
rte
ns
io
n
18
-6
5 y
ea
r o
ld
 
ad
ul
ts 
wh
o v
is-
ite
d 2
3 c
om
m
u-
ni
ty
 ph
ar
m
ac
ies
 
to
 ch
ec
k f
or
 M
etS
 
ris
k f
ac
to
rs
Sc
re
en
 of
 pa
r-
tic
ip
an
ts 
fo
r 
pr
e-
M
etS
 an
d 
ca
rd
io
va
sc
ul
ar
 
ris
k f
ac
to
rs 
in
clu
di
ng
 pa
tie
nt
 
in
ter
vi
ew
s a
nd
 
m
ea
su
re
m
en
t o
f 
ap
pr
op
ria
te 
m
eta
-
bo
lic
 pa
ra
m
ete
rs
Ea
rli
er
 de
tec
tio
n 
of
 M
etS
 th
ro
ug
h 
ph
ar
m
ac
ist
-
led
 sc
re
en
in
g 
pr
og
ra
m
 (2
7%
 
ne
ve
 di
ag
no
se
d 
wi
th
 H
TN
 or
 
dy
sli
pi
de
m
ia)
M
en
Ol
de
r a
du
lts
 
(a
ge
 >
 53
 ye
ar
s 
ol
d)
 w
ith
BM
I >
 25
 kg
/m
2  
Se
de
nt
ar
y l
ife
-
sty
le 
(le
ss
 th
an
 
30
 m
in
 re
gu
lar
 
ac
tiv
ity
 4 
to
 5 
tim
es
 pe
r w
ee
k)
Fa
ci
lit
at
or
s
Co
m
m
un
ity
 ph
ar-
m
ac
y s
ett
in
g p
lac
-
in
g t
he
 ph
ar
m
ac
ist
 
in
 an
 ex
ce
lle
nt
 
po
sit
io
n t
o p
ro
vi
de
 
a s
cr
ee
ni
ng
 se
rv
ice
Av
ail
ab
le 
re
so
ur
ce
 
su
ch
 as
 P
OC
 
de
vi
ce
s
Ba
rr
ie
rs
La
ck
 of
 fi
na
nc
ial
 
su
pp
or
t i
nc
lu
di
ng
 
th
at 
fo
r s
taff
 an
d 
co
ns
um
ab
les
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tifi
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lat
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fro
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pu
t
Fa
cil
ita
to
rs 
an
d b
ar-
rie
rs 
to
 th
e e
ffe
cti
ve
 
im
pl
em
en
tat
io
n o
f 
M
etS
Sc
hn
eid
er
ha
n e
t a
l.,
 
20
14
, M
in
ne
so
ta 
[4
0]
”T
o d
ete
rm
in
e t
he
 
pe
rc
en
tag
e o
f 
su
bj
ec
ts 
tak
in
g 
an
tip
sy
ch
ot
ic 
ag
en
ts 
wh
o m
ee
t 
th
e c
rit
er
ia 
fo
r 
M
etS
 at
 ba
se
lin
e 
us
in
g P
OC
 te
st 
re
su
lts
. S
ec
on
d-
ar
y o
bj
ec
tiv
es
 
in
clu
de
d t
he
 
fo
llo
wi
ng
 (1
) 
ev
alu
ate
 th
e 
eff
ec
tiv
en
es
s o
f 
th
e p
re
vi
sio
n 
by
 ph
ar
m
ac
ist
 
co
m
pr
eh
en
siv
e 
m
ed
ica
tio
n m
an
-
ag
em
en
t s
er
vi
ce
s 
re
ga
rd
in
g t
he
ir 
ab
ili
ty
 to
 re
du
ce
 
th
e m
ea
n d
iff
er-
en
ce
 in
 nu
m
be
r 
of
 M
etS
 ri
sk
 
pa
ra
m
ete
rs 
ba
se
d 
on
 P
OC
 te
st 
re
su
lte
d a
t 6
 an
d 
12
 m
on
th
s a
nd
 
(2
) e
va
lu
ate
 th
e 
ov
er
all
 im
pa
ct 
of
 
ps
yc
hi
atr
ic 
m
ed
i-
ca
tio
n t
he
ra
py
 on
 
M
etS
”
RC
T 
no
n-
bl
in
de
d
At
 ba
se
lin
e o
f 
12
0 p
ar
tic
ip
an
ts 
sc
re
en
ed
, 1
06
 
(8
8.3
%)
 ha
d 
dy
sli
pi
de
m
ia,
 
63
 (5
2.5
%)
 w
er
e 
hy
pe
rte
ns
ive
 
an
d 2
7 (
22
.5%
) 
we
re
 di
ab
eti
c. 
No
 si
gn
ifi
ca
nt
 
di
ffe
re
nc
e i
n 
M
etS
 pa
ra
m
ete
rs 
be
tw
ee
n g
ro
up
s 
at 
6 m
on
th
s a
nd
 
12
 m
on
th
s. 
No
 
sig
ni
fic
an
t d
if-
fer
en
ce
 re
po
rte
d 
be
tw
ee
n p
ar
am
-
ete
rs 
irr
es
pe
cti
ve
 
of
 an
tip
sy
ch
ot
ic
Pa
tie
nt
s 1
8 y
ea
rs 
an
d o
ve
r, 
tak
in
g 
an
tip
sy
ch
ot
ic 
m
ed
ica
tio
ns
 
re
cr
ui
ted
 fr
om
 
th
re
e c
om
m
un
ity
 
m
en
tal
 he
alt
h 
cli
ni
cs
 w
ho
 
ha
d n
ev
er
 be
en
 
re
vi
ew
ed
 by
 a 
ph
ar
m
ac
ist
Ba
se
lin
e a
ss
es
s-
m
en
t o
f M
etS
 
ris
k f
ac
to
rs 
am
on
gs
t p
ati
en
ts 
re
ce
iv
in
g a
nt
ip
sy
-
ch
ot
ic 
m
ed
ica
-
tio
ns
As
se
ss
m
en
t o
f 
th
e s
afe
ty
 an
d 
eff
ec
tiv
en
es
s o
f 
th
e p
re
sc
rib
ed
 
m
ed
ica
tio
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Fo
llo
w 
up
 of
 
pa
tie
nt
s a
t r
eg
ul
ar
 
in
ter
va
ls
Pr
ov
isi
on
 of
 th
e 
in
ter
pr
eta
tio
n o
f 
PO
C 
tes
t r
es
ul
ts,
 
ca
re
 pl
an
s, 
an
d 
re
co
m
m
en
da
tio
ns
 
to
 th
e p
hy
sic
ian
Ea
rli
er
 de
tec
tio
n 
of
 M
etS
 th
ro
ug
h 
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ar
m
ac
ist
-
led
 sc
re
en
in
g 
pr
og
ra
m
 al
lo
wi
ng
 
ea
rli
er
 m
an
ag
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m
en
t
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ten
tia
l d
ec
re
as
e 
dr
ug
-in
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ce
d 
M
etS
 am
on
gs
t 
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yc
hi
atr
ic 
pa
tie
nt
s r
ec
eiv
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an
tip
sy
ch
ot
ics
Ps
yc
hi
atr
ic 
pa
tie
nt
s 
wh
o a
re
 re
ce
iv-
in
g a
nt
ip
sy
ch
ot
-
ics
Fa
ci
lit
at
or
s
Av
ail
ab
ili
ty
 of
 th
e 
PO
C 
de
vi
ce
s p
ar-
tic
ul
ar
ly
 du
e t
o t
he
 
ch
all
en
gi
ng
 be
ha
v-
io
ur
 of
 ps
yc
hi
atr
ic 
pa
tie
nt
s
Be
in
g a
 pa
rt 
of
 th
e 
m
ul
tid
isc
ip
lin
ar
y 
tea
m
 (M
DT
) w
ith
 a 
de
fin
ed
 ro
le
Ba
rr
ie
rs
Ch
all
en
gi
ng
 be
ha
v-
io
ur
s o
f p
sy
ch
iat
ric
 
pa
tie
nt
s
La
ck
 of
 fi
na
nc
ial
 
su
pp
or
t i
nc
lu
di
ng
 
th
at 
fo
r s
taff
 an
d 
co
ns
um
ab
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pu
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ho
 
wo
ul
d b
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fro
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pu
t
Fa
cil
ita
to
rs 
an
d b
ar-
rie
rs 
to
 th
e e
ffe
cti
ve
 
im
pl
em
en
tat
io
n o
f 
M
etS
Az
ev
ed
o e
t a
l. 
20
17
, B
ra
zil
 [4
4]
“T
o e
va
lu
ate
 
th
e e
ffe
cti
ve
-
ne
ss
 of
 ho
m
e 
ph
ar
m
ac
eu
tic
al 
in
ter
ve
nt
io
ns
 in
 
Br
az
ili
an
 pr
im
ar
y 
ca
re
 pa
tie
nt
s w
ith
 
M
etS
”
RC
T 
no
n-
bl
in
de
d
63
 pa
tie
nt
s w
ith
 
M
etS
 w
er
e 
en
ro
lle
d i
n t
he
 
stu
dy
. 6
4.5
% 
(n
 =
 49
) o
f p
ha
r-
m
ac
ist
s’ 
in
ter
-
ve
nt
io
ns
 w
er
e 
ed
uc
ati
on
al 
an
d 
be
ha
vi
ou
ra
l o
ri-
en
tat
io
n. 
26
.3%
 
(n
 =
 20
) i
nv
ol
ve
d 
ph
ys
ici
an
 re
qu
es
t-
in
g r
ev
iew
, a
nd
 
9.2
% 
(n
 =
 7)
 of
 
th
e c
as
es
 w
er
e 
re
fer
re
d t
o t
he
 
ph
ys
ici
an
 fo
r f
ur
-
th
er
 as
se
ss
m
en
t.
Af
ter
 6 
m
on
th
s 
fo
llo
w-
up
, t
he
 
in
ter
ve
nt
io
n 
gr
ou
p s
ho
we
d a
 
sig
ni
fic
an
t r
ed
uc
-
tio
n o
f B
P 
by
 8%
, 
TG
 by
 18
.7%
, 
DR
Ps
 by
 59
% 
an
d 
ad
he
re
nc
e i
nc
re
-
m
en
t b
y 1
8.2
%
Ad
ul
t p
ati
en
ts 
ag
ed
 
18
 ye
ar
s a
nd
 
ov
er
 di
ag
no
se
d 
wi
th
 M
etS
 w
ith
in
 
30
 da
ys
Ba
se
lin
e a
ss
es
s-
m
en
t o
f b
ot
h 
gr
ou
ps
M
on
th
ly
 fo
llo
w-
up
s o
f t
he
 
in
ter
ve
nt
io
n 
gr
ou
p, 
in
clu
di
ng
 
th
e f
ol
lo
wi
ng
 
ac
tiv
iti
es
:
Re
vi
ew
in
g m
ed
ica
-
tio
ns
, i
de
nt
ifi
ca
-
tio
n o
f D
RP
s t
ha
t 
m
ig
ht
 de
cr
ea
se
 
th
e a
dh
er
en
ce
 
an
d r
es
ol
vi
ng
 
th
em
Pr
ov
id
e e
du
ca
tio
n 
ab
ou
t a
dm
in
ist
ra
-
tio
n a
nd
 st
or
ag
e
Di
et 
an
d l
ife
sty
le 
re
co
m
m
en
da
tio
ns
Id
en
tif
y a
ny
 un
ad
-
dr
es
se
d m
ed
ica
l 
pr
ob
lem
Im
pr
ov
e t
he
 m
an
-
ag
em
en
t o
f M
etS
 
an
d t
he
 in
di
vi
d-
ua
l c
om
po
ne
nt
s 
(re
du
cti
on
 of
 B
P 
by
 8%
, T
G 
by
 
18
.7%
)
Fo
ste
r m
ed
ica
tio
n 
ad
he
re
nc
e b
y 
18
.2%
De
cr
ea
se
 th
e D
RP
s 
by
 59
%
Ol
de
r p
ati
en
ts 
wi
th
 M
etS
 m
ea
n 
ag
e 6
2 y
ea
rs 
pa
rti
cu
lar
ly
 if
 
(lo
w 
in
co
m
e a
nd
 
lo
w 
ed
uc
ati
on
al 
lev
el)
Fa
ci
lit
at
or
s
Co
lla
bo
ra
tio
n w
ith
 
M
DT
Ap
pl
yi
ng
 st
an
da
rd
-
ize
d c
ar
e p
ha
rm
a-
ce
ut
ica
l c
ar
e p
lan
 
[6
1]
Th
e s
ett
in
gs
 of
 ho
m
e 
vi
sit
s
Ba
rr
ie
rs
No
 id
en
tifi
ed
 ba
r-
rie
rs
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rs 
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d b
ar-
rie
rs 
to
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e e
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cti
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im
pl
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en
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io
n o
f 
M
etS
Ga
nz
er,
 N
ico
le 
20
15
, W
es
t P
alm
 
Be
ac
h [
45
]
To
 ev
alu
ate
 th
e 
nu
m
be
r o
f 
ph
ar
m
ac
ol
og
ic 
ph
ar
m
ac
ist
in
ter
ve
nt
io
ns
, 
as
se
ss
 th
e n
um
be
r 
of
 no
np
ha
rm
ac
o-
lo
gi
c
in
ter
ve
nt
io
ns
, a
nd
 
co
m
pa
re
 th
e 
pa
tie
nt
 lo
ad
 po
st 
ex
pa
ns
io
n
to
 th
e p
ilo
t i
m
pl
e-
m
en
tat
io
n o
f t
he
 
m
eta
bo
lic
 cl
in
ic.
Qu
ali
ty
 im
pr
ov
e-
m
en
t p
ro
jec
t
Th
e i
ni
tia
l p
ilo
t 
cli
ni
c h
ad
 40
 
re
fer
ra
ls,
 of
 
th
em
 25
 w
er
e 
fo
llo
we
d u
p. 
Th
e 
ne
w 
ex
pa
nd
ed
 
cli
ni
c r
ec
eiv
ed
 
28
 re
fer
ra
ls 
wi
th
 
17
 fo
llo
we
d u
p. 
Tw
en
ty
-fi
ve
 
ph
ar
m
ac
ol
og
i-
ca
l (
in
iti
ate
 ne
w 
m
ed
ica
tio
ns
 or
 
do
se
 ad
ju
stm
en
t) 
an
d 3
3 n
on
ph
ar-
m
ac
ol
og
ica
l 
in
ter
ve
nt
io
ns
 
(d
iet
 an
d e
xe
r-
cis
e)
 w
er
e m
ad
e. 
Th
re
e r
efe
rra
ls 
to
 
na
tio
na
l w
eig
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[46]. One study included children and adolescents at high-
risk of MetS, with a first-degree family history of type 2 
DM, obesity or acanthosis nigricans [42], due to the poten-
tial link to underlying insulin resistance [47, 48]. Healthy 
volunteers were the subjects of one study [36] (Table 3).
Review objective 4: Facilitators and barriers
None of the studies specifically aimed to determine the 
facilitators and barriers to pharmacist input. Consequently, 
data relating to facilitators and barriers were extracted by 
the reviewers. Throughout all studies, the most commonly 
identified facilitator was effective communication, documen-
tation and appropriate setting for MDT referrals, in addition 
to active collaboration with the MDT where each member of 
the MDT had a defined role (Table 4). Lack of funding for 
reimbursement of pharmacist time, purchasing consumables 
and other resources such as IT software was the most com-
mon barrier identified to the effective implementation of the 
pharmacist-led activity. Challenging behaviour of psychiat-
ric patients was reported as a barrier in all studies involving 
psychiatric patients (Table 4).
Discussion
This is the first published systematic review focusing specifi-
cally on pharmacist input in MetS. This review identified 
ten studies, four of which were RCTs. The most frequently 
reported inputs were in screening and in management, with 
prevention-related activities described in one study. The 
main population studied was adults with comorbidities 
putting them at higher risk of developing MetS. Benefi-
cial impacts were described in terms of earlier diagnosis, 
potentially earlier intervention and improvement in the MetS 
parameters. Successful integration with the MDT, effective 
communication and accessibility of the community pharma-
cies were most likely facilitators towards the implementation 
with lack of funding the most likely barrier.
This review adhered to best practice in conducting and 
reporting a systematic review, as described in “Preferred 
Reporting Items for Systematic Reviews and Meta-Analy-
ses” (PRISMA) [49] (Online Appendix A). The wide range 
of patient populations reported in the studies may enhance 
the generalisability of findings to at-risk populations. 
The main review limitation was restricting the review to 
papers published in English, resulting in four studies not 
being included. While the quality of the studies was gener-
ally good, reporting could be enhanced by encouraging the 
authors to adopt robust reporting criteria such as those rec-
ommended by the EQUATOR (Enhancing the QUAlity and 
Transparency Of health Research) network [50, 51].
This systematic review has identified limited evidence 
upon which to inform the best practice of pharmacist input 
to MetS. The evidence base is derived from ten studies, 
only four of which were RCTs. Of the ten studies, there 
was marked variation in the aims and the models of care 
delivered, which significantly limits any potential for data 
pooling. Indeed, only four studies provided a comprehensive 
description of pharmacist interventions in terms of defined 
activities, training, processes, documentation, outcomes to 
be recorded and follow-ups.
A pharmacist-based intervention around MetS could be 
argued to be a complex intervention as defined by the UK 
Medical Research Council (MRC) which defines a ‘complex 
intervention’ as one with several interacting components, 
involving different behaviours and variability in outcomes 
[52]. The MRC complex intervention framework has four 
stages of development, feasibility/pilot testing, evaluation 
and implementation. It is worth noting that none of the ten 
studies in this systematic review included all these stages, 
with particular deficiencies around the development, fea-
sibility and pilot testing stages. Ideally, the interventions 
should be developed and informed by evidence base in the 
literature (e.g. a systematic review), consider the theoreti-
cal basis for the intervention (e.g. behaviour change theory) 
and involve all stakeholders in development. Interventions 
developed according to this system are more likely to be 
successful compared to those developed pragmatically [52, 
53]. There is also a lack of consideration of the MRC frame-
work in the primary studies included in previous systematic 
reviews describing pharmacists input to managing Mets ele-
ments such DM [54], HTN [19], obesity [21] and cardiovas-
cular risk factors [55].
Despite the absence of application of the MRC frame-
work, this review has provided some evidence of the benefit 
of the pharmacist input, particularly in the screening for 
and management of MetS. There were positive outcomes 
of earlier diagnosis, referrals to the pertinent physician and 
reaching the MetS parameter goals.
Obese adults with chronic comorbid conditions and pae-
diatrics with risk factors were identified in this review to be 
among the beneficiary populations. These findings concur 
with at-risk populations highlighted by international organi-
zations. Moreover, the American Heart Association (AHA) 
and NHLBI underpin obesity and prediabetes as the main 
risk factors to develop MetS, in addition to other risk factors 
such as a sedentary lifestyle, atherogenic diet and older age 
[13]. This was further supported by the IDF communica-
tion consensus worldwide de-finition of MetS in 2006. Cen-
tral obesity and insulin resistance were defined as the most 
potent risk factors to develop MetS, in addition to other risk 
factors such as; ageing, genetic predisposition, sedentary 
lifestyle, proinflammatory status and reproductive hormonal 
alteration [3]. Hence, prioritizing the at-risk population is 
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logical and would be recommended, especially at the initial 
phase of implementing pharmacist-led activity with limited 
resource and experience.
Additionally, patients receiving antipsychotic medications 
were recognized by the American Psychiatric Association 
(APA) as at-risk population for development of MetS due 
to the strong association with weight gain, dyslipidemia and 
hyperglycemia, and emphasized the importance of regular 
screening and monitoring of MetS [56]. This supports the 
fact that psychiatric patients were also among the beneficiary 
populations identified in this review.
The challenges facing the implementation of the phar-
macist within the collaborative service involving different 
specialities, including mental health, are common. While 
the nature of the conditions and the interventions are varied, 
the need for effective collaboration remains. The findings of 
a systematic review of 18 studies reporting the facilitators 
and barriers to the implementation of collaborative practice 
in mental health were in line with the findings of the cur-
rent review. To successfully implement a new collaborative 
service, Wood and colleagues emphasised the importance 
of adopting a multidisciplinary approach in mental health, 
including a pharmacist, maintaining effective communica-
tions, applying structured care plans and sustaining active 
patient’s follow-up. On the other hand, the readiness of 
the organisations and staff for implementation and lack of 
knowledgeable, self-confident staff, adequate supervision 
and resources were the more pronounced barriers reported 
by Wood et al. [57].
A meta-synthesis of 29 qualitative studies categorized 
the influencing factors (facilitators and barriers) of imple-
menting an advanced pharmacist run patient centred service 
into four categories; the patients’ factors, the interpersonal 
communication factors, organizational and community fac-
tors [58]. Among the most prominent factors enhancing 
implementation of advanced pharmaceutical services were 
easy accessibility of the service, sufficient resources for IT 
programmes, educational materials, service promotion, staff 
incentives, effective collaboration and communication and 
a predesigned protocol to define the role of each member of 
the team. The lack of these factors was barriers to imple-
mentation of the services [58]. This is similar to findings in 
this reported systematic review, for example in our study, 
organizational factors such as limited resources were also a 
barrier to implementation of pharmacist input to MetS; the 
interpersonal communication factors such as effective col-
laboration and communication with other healthcare provid-
ers were considered a facilitator, and specific patient factors 
including the challenging behaviour of psychiatric patients 
was a barrier to the practical implementation (Table 4).
The findings of this review are consistent with several 
published systematic reviews that have suggested that the 
MDT-pharmacist collaboration is the best model of care and 
facilitated the pharmacist’s role in screening and manage-
ment of patients with MetS. Showande et al. confirmed the 
effectiveness of collaborative pharmacist management of 
Type 1 and Type 2 DM with 41 RCTs included in a system-
atic review and meta-analysis [54]. Similarly, in an earlier 
published systematic review by Altowaijri et al. across dif-
ferent settings (inpatient, outpatients and community phar-
macies), pharmacist involvement with the MDT in second-
ary prevention of cardiovascular diseases was associated 
with better control of the cardiovascular risk factors and 
improvement in the clinical outcome [55].
Of paramount importance, emerging studies have sug-
gested strategies to overcome the barriers to the implementa-
tion of collaborative pharmacist service. A meta-synthesis 
of 29 qualitative studies as well as the collaborative practice 
agreement issued by the national center for chronic disease 
prevention and health promotion, both have advocated uti-
lizing evidence-informed practice along with seeking sup-
port from a leading champion in the field were suggested to 
alleviate the organisational and staff reluctance toward the 
implementation of new collaborative services. A multidis-
ciplinary approach with engaging patients and their fami-
lies was recommended to increase the readiness of the staff 
and patients to accept the pharmacist service. Emphasizing 
the potential long-term healthcare cost reduction secondary 
to the pharmacist collaboration and having more than one 
source of funding and cutting unnecessary expenses were 
suggested to overcome the financial barrier [59, 60].
Implications for the further research phase
This systematic review highlighted the gap in the literature 
and provided evidence about the more effective model-of-
care for the pharmacist to intervene in MetS. Future research 
is warranted to define the potential patient-centred model 
of care that should be systematically developed, evalu-
ated, implemented and refined based on the MRC evalua-
tion framework. Additionally, further qualitative research 
to explore in-depth the patients’ behaviours and health care 
professionals’ perception of the MDT collaborative practice 
will inform the development of a successful model of care.
Conclusion
The limited number of studies describing pharmacist input 
in MetS provides some evidence of positive outcomes from 
screening and management as part of collaborative practice. 
Further work is required to provide more robust evidence 
of effectiveness and cost-effectiveness, while considering 
key barriers, to enable integration within standard practice.
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